Melissa Epperly - 04 Apr 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Signature
By: /s/ Melissa B. Epperly
Issuer symbol
ZNTL
Transactions as of
04 Apr 2022
Transactions value $
-$855,522
Form type
4
Filing time
05 Apr 2022, 18:53:12 UTC
Previous filing
23 Feb 2022
Next filing
15 Jun 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale -$394,562 -8,094 -3.06% $48.75 256,400 04 Apr 2022 Direct F1, F2
transaction ZNTL Common Stock Sale -$65,022 -1,303 -0.51% $49.9 255,097 04 Apr 2022 Direct F1, F3
transaction ZNTL Common Stock Sale -$142,865 -2,818 -1.1% $50.7 252,279 04 Apr 2022 Direct F1, F4
transaction ZNTL Common Stock Sale -$234,561 -4,512 -1.79% $51.99 247,767 04 Apr 2022 Direct F1, F5
transaction ZNTL Common Stock Sale -$18,510 -353 -0.14% $52.44 247,414 04 Apr 2022 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $48.35 to $49.33. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.38 to $50.37. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.38 to $51.32. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.41 to $52.40. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.41 to $52.54. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.